reports
Team Member Feedback Earns HealthEquity Workplace Culture Recognition
Team Member Feedback Earns HealthEquity Workplace Culture Recognition For the fourth consecutive year, team members' feedback has propelled HealthEquity to be recognized for cultural excellence DRAPER, Utah, May 02, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY), the nation’s largest Health Savings Account (HSA) custodian has received a Culture Excellence Award by Top Workplaces for the fourth consecutive year. "Our teammates deserve all the credit when it comes to this award,” said Cheryl King, executive vice president and chief human resource officer. “They have embraced o...
Moody's Ratings affirms W&T Offshore's B3 CFR with negative outlook
Moody's Ratings (Moody's) changed W&T Offshore, Inc.'s (W&T) outlook to negative, from stable previously. Concurrently, Moody's affirmed W&T's B3 Corporate Family Rating (CFR), B3-PD Probability of Default Rating (PDR), and Caa1 senior secured second lien notes rating. "The change in W&T's outlook...
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Produ...
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalmic suspensions to be dispensed with the Optejet® NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), a commercial-stage ophthalmic company, today provided an upd...
Angi Inc. to Announce Q1 2024 Earnings on May 7th and Host Earnings Co...
Angi Inc. to Announce Q1 2024 Earnings on May 7th and Host Earnings Conference Call on May 8th DENVER, April 16, 2024 (GLOBE NEWSWIRE) -- After the close of market trading on Tuesday, May 7, 2024, Angi Inc. (NASDAQ: ANGI) will post its first quarter results at . On Wednesday May 8, 2024, at 8:30 a.m. ET, Angi Inc. and IAC will host a conference call to answer questions regarding the companies’ respective first quarter results. The live audiocast and replay will be open to the public through the investor relations section of the Angi site at . About Angi Inc. Angi (NASDAQ: ANGI) helps...
Angi Appoints Jeff Kip as CEO
Angi Appoints Jeff Kip as CEO DENVER, April 08, 2024 (GLOBE NEWSWIRE) -- Angi (NASDAQ: ANGI), the leading and most comprehensive solution for all home care needs, today announced the appointment of Angi President and long-time IAC and Angi executive Jeff Kip to CEO, succeeding Joey Levin. As CEO, Mr. Kip will lead Angi’s executive team, overseeing strategy and daily management of the company. Mr. Levin, CEO of IAC, will continue as Chairman of the Angi Board of Directors. All changes are effective immediately. “Through multiple roles, Jeff Kip has been a student of the Angi business, fir...
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus ...
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and a potential NDA to the FDA in 2025Continuing to advance commercialization of Mydcombi for mydriasis and preparing to launch clobetasol propionate ophthalmic suspension 0.05% for post-surgical management of pain and inflammation; both represent large multi-million-dollar opportunitiesCompany explori...
Benefits Leaders Believe in Power of AI, Considering Data Privacy and ...
Benefits Leaders Believe in Power of AI, Considering Data Privacy and Accuracy New study indicates that benefits professionals are in an ‘early adopter’ stage with AI DRAPER, Utah, April 04, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (Nasdaq: HQY) ("HealthEquity") released the findings of a new survey on Artificial Intelligence (AI) in benefits administration. The survey provides a benchmark on senior benefit leaders’ attitude toward AI-enabled benefits tools. A majority (73%) of the more than 800 respondents surveyed believe that AI will have a positive influence on benefits adminis...
Eyenovia to Feature its Suite of Commercial Products and the Optejet D...
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings Company to demonstrate Mydcombi™ and Avenova® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 5-8, in Boston Will also demonstrate and discuss commercial terms for Mydcombi at the Vision Source Exchange, April 10-13, in Orlando NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced that the comp...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
OPK OPKO HEALTH INC.
NYCB NEW YORK COMMUNITY BANCORP INC.
MHLD MAIDEN HOLDINGS LTD.
GOGO GOGO INC.
DLTR DOLLAR TREE INC.
CTRN CITI TRENDS INC.
CRMT AMERICA'S CAR-MART INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
AAOI APPLIED OPTOELECTRONICS INC.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
VICI VICI PROPERTIES INC
CDLX CARDLYTICS INC
TALO TALOS ENERGY INC.
STKS THE ONE GROUP HOSPITALITY INC.
PAYS PAYSIGN INC
REEMF RARE ELEMENT RESOURCES
DCTH DELCATH SYSTEMS
RZLT REZOLUTE
MYO INC.
XERS MYOMO
LEE XERIS BIOPHARMA HLDGS INC
QSI LEE ENTERPRISES INC
ASLE QUANTUM-SI INC
VPV AERSALE CORP
BPRN INVESCO PA VALUE MUNI INC TST
CYT BANK OF PRINCETON
CYTEIR THERAPEUTICS INC
HealthEquity Reports Fiscal Year and Fourth Quarter Ended January 31, ...
HealthEquity Reports Fiscal Year and Fourth Quarter Ended January 31, 2024 Financial Results Highlights of the fiscal year include: Revenue of $999.6 million, an increase of 16% compared to $861.7 million in FY23.Net income of $55.7 million, compared to net loss of $26.1 million in FY23, with non-GAAP net income of $195.5 million, compared to $114.5 million in FY23.Net income per diluted share of $0.64, compared to net loss per diluted share of $0.31 in FY23, with non-GAAP net income per diluted share of $2.25, compared to $1.36 in FY23.Adjusted EBITDA of $369.2 million, an increase of 36%...
Opko Health Inc: 1 director
A director at Opko Health Inc bought 500,000 shares at 0.874USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
- Jonathan Moreland
GOGO GOGO INC.
DLTR DOLLAR TREE INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
AAOI APPLIED OPTOELECTRONICS INC.
VICI VICI PROPERTIES INC
CDLX CARDLYTICS INC
CSPI CSP INC.
PAYS PAYSIGN INC
HRMY HARMONY BIOSCIENCES HOLDINGS
MYO MYOMO
CLOV CLOVER HEALTH INV CORP
IMRX IMMUNEERING CORP
XERS XERIS BIOPHARMA HLDGS INC
SPRB SPRUCE BIOSCIENCES INC
QSI QUANTUM-SI INC
ASLE AERSALE CORP
BPRN BANK OF PRINCETON
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results a...
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery Reacquired development and commercialization rights to MicroPine for progressive pediatric myopia in the U.S. and Canada Continued to advance commercial operations with launch of Mydcombi™, FDA approval of manufacturing facility, onboarding of sales organization and signing of copromotion agreement Company to host conference call and webcast today, Ma...
- Jonathan Moreland
TLYS TILLYS
SSNC SS&C TECHNOLOGIES HOLDINGS INC.
OPK OPKO HEALTH INC.
HOO HERBALIFE NUTRITION LTD.
CTRN CITI TRENDS INC.
CE CELANESE CORPORATION
BANC BANC OF CALIFORNIA INCORPORATED
HWBK HAWTHORN BANCSHARES
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
JFR NUVEEN FLOATING RATE INCOME FUND
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
AYX ALTERYX
FMN FEDERATED PREMIER MUNICIPAL INCOME FUND
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
QNBC QNB CORP.
TALO TALOS ENERGY INC.
RBB RBB BANCORP
AXR AMREP
SKYE NEMUS BIOSCIENCE INC
ELAN ELANCO ANIMAL HEALTH INC.
ANIX ANIXA BIOSCIENCES
PAYS PAYSIGN INC
KSM DWS STRATEGIC MUNICIPAL INCOME TRUST
VTN INVESCO TRUST FOR INVESTMENT G
RZLT REZOLUTE
COOK INC.
MPA TRAEGER
FRST INC.
ASLE BLACKROCK MUNIYIELD PENNSYLVANIA FD
VPV PRIMIS FINANCIAL CORP
BPRN AERSALE CORP
CRBP INVESCO PA VALUE MUNI INC TST
LSXMK BANK OF PRINCETON
BHRB CORBUS PHARMACEUTICALS HOLDINGS INC.
MDRX LIBERTY SIRIUSXM GROUP
APRE BURKE HERBERT FINANCIAL SERVICES CORP
ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS
INC.
APREA THERAPEUTICS INC
- Jonathan Moreland
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophtha...
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Under the agreement, NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension 0.05% (“Clobetasol”), a steroid indicated for the treatment of inflammation and pain follow...
- Jonathan Moreland
OPK OPKO HEALTH INC.
HOO HERBALIFE NUTRITION LTD.
CTRN CITI TRENDS INC.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
FMN FEDERATED PREMIER MUNICIPAL INCOME FUND
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
QNBC QNB CORP.
ELAN ELANCO ANIMAL HEALTH INC.
ZM ZOOM VIDEO COMMUNICATIONS
KSM INC.
VTN DWS STRATEGIC MUNICIPAL INCOME TRUST
MPA INVESCO TRUST FOR INVESTMENT G
VPV BLACKROCK MUNIYIELD PENNSYLVANIA FD
LSXMK INVESCO PA VALUE MUNI INC TST
LIBERTY SIRIUSXM GROUP
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Up...
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th Company to host an investor conference call and webcast at 4:30pm EDT NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), a commercial-stage ophthalmic pharmaceutical technology company, today announced that the Company will release financial results for the fourth quarter ended December 31, 2023 on Monday, March 18th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. ET to review the financial and operati...
HealthEquity Sets Date to Announce Fiscal Year End Results
HealthEquity Sets Date to Announce Fiscal Year End Results DRAPER, Utah, March 05, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced plans to release its fourth quarter and fiscal year end 2024 financial results following the close of regular stock market trading hours on Tuesday, March 19, 2024. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, March 19, 2024, at 4:30 p.m. ET during which management will revi...
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX...
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV • Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans• Candidate showed similar half-life to standard monoclonal antibodies and minimal anti-drug antibodies WESTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing ant...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.